Centrilobular emphysema combined with pulmonary fibrosis results in improved survival

Table 1 Characteristics of the overall patient cohort (n = 102).

Age, years, median [1^st, 3^rd]	61 [55, 66]
Gender:
Male, n	66
Female, n	36
Race:
Caucasian, n	69
African-American, n	28
Other, n	5
Medication:
Prednisone, n	88
Azathioprine, n	49
Mycophenolate, n	27
N-Acetylcysteine, n	42
ACE Inhibitor, n	19
Statin, n	45
Smoking history:
Never, n (%)	31 (30)
Ever, n (%)	71 (70)
Right heart catheterization:
Performed, n (%)	76 (75)
PH present, n (%)	31 (41)
Surgical lung biopsy:
Performed, n (%)	73 (71)
UIP, n	60
Fibrotic NSIP, n	13
Pulmonary function tests:
FVC [% predicted; median (1st, 3rd)]	54 [42, 66]
TLC [% predicted; median (1st, 3rd)]	54 [42, 64]
DL_CO [% predicted; median (1st, 3rd)]	28 [20, 36]

PH, pulmonary hypertension (defined by mean pulmonary artery pressure > 25 mm Hg); UIP, usual interstitial pneumonia; NSIP, non-specific interstitial pneumonia; FVC, forced vital capacity; TLC, total lung capacity; DL_CO, diffusing capacity for carbon monoxide.

ISSN: 1755-1536